Tandem Diabetes Care (Nasdaq:TNDM) today announced an agreement to develop and commercialize diabetes tech with Abbott (NYSE:ABT). San Diego–based Tandem said it agreed to combine its insulin delivery systems with Abbott’s future dual glucose-ketone sensor. The companies aim to provide more options for people to manage their diabetes. This marks the second recent collaboration announcement […]
abbott
Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
Sequel Med Tech announced today that it agreed to integrate its twiist automated insulin delivery system with a future Abbott sensor. The companies agreed to pair twiist, powered by Tidepool, with Abbott‘s glucose-ketone sensor, currently under development. Sequel said the agreement aims to improve outcomes for people with type 1 diabetes. It adds ketone sensing capabilities […]
Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. Data demonstrated that CGM can help lessen the severity […]
Abbott integrates Libre CGM data into Epic EHR workflows
Abbott (NYSE:ABT) announced today that it entered a first-of-its-kind agreement to integrate data from its Libre systems into Epic EHR systems. The partnership enables the integration of data from the Libre continuous glucose monitor (CGM) systems directly into Epic EHR in the U.S. Through this collaboration, the companies aim to improve workflow efficiency for providers […]
Medtronic submits interoperable insulin pump to FDA to advance collaboration with Abbott
Medtronic (NYSE:MDT) announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable insulin pump. Clearance would enable system integration with a continuous glucose monitor (CGM) sensor based on Abbott’s most advanced platform. This marks the latest development in a landmark collaboration between the two medtech giants. Last summer, the companies […]
Abbott launches universal FreeStyle Libre CGM app in U.S.
Abbott (NYSE: ABT) recently launched a smartphone app that works with both its FreeStyle Libre 2 and FreeStyle Libre 3 continuous glucose monitoring systems. “By listening to our customers, we developed a universal app with enhanced features to make living with diabetes easier,” Badia Boudaiffa, VP of North America commercial operations for Abbott’s diabetes care […]
Glooko integrates diabetes management platform with Abbott FreeStyle Libre
Glooko announced today that its platform now supports the Abbott FreeStyle Libre continuous glucose monitoring (CGM) in the U.S. The integration further strengthens Glooko’s commitment to offering a comprehensive, all-in-one solution for managing diabetes. Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Sequel Med Tech makes first CGM integration with Abbott for automated insulin pump
Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor. This marks the first continuous glucose monitor (CGM) integration for twiist. Manchester, New Hampshire-based Sequel expects to launch the combination in the second quarter of 2025. Sequel won FDA clearance for the twiist […]
Abbott inks first Lingo retail deal with Amazon
Abbott (NYSE:ABT) announced that it made its Lingo continuous glucose monitoring (CGM) system available for purchase on Amazon. The CGM, which utilizes a single sensor for up to 14 days and doesn’t require a prescription, retails for $49 on the popular online marketplace. It also has eligibility on Amazon Prime, where available. Lingo, an over-the-counter […]
